Chronic atrophic gastritis (CAG) is characterized by mucosal atrophy due to prolonged inflammation, leading to compromised mucosal barrier integrity and mitochondrial dysfunction. Artemisinin B (ATB), a derivative of artemisinin with potent anti-inflammatory properties, has shown therapeutic potential for CAG but is limited by poor oral bioavailability. To overcome this, an amino-functionalized BYON nanocarrier system (BYON-ATB) was developed, enhancing mucoadhesion through surface charge modification and enabling targeted drug release in the gastric environment. BYON-ATB significantly outperformed free ATB in reducing inflammation, oxidative stress, and barrier dysfunction, and importantly, promoted gastric atrophy regeneration in vivo. This regenerative effect was driven by the restoration of mitochondrial structure and function, including improved membrane potential, inhibited mPTP opening, and increased ATP production. Mechanistically, BYON-ATB upregulated the mitochondrial calcium uptake regulator MICU1, thereby restoring mitochondrial calcium homeostasis. This study highlights MICU1 as a promising therapeutic target in CAG and demonstrates that BYON-ATB facilitates gastric atrophy regeneration via inflammation, oxidative stress, and barrier disruption through MICU1-mediated mitochondrial calcium homeostasis.